Aim To synthesize cytarabine loaded SLNs modified with the RGD peptide as a ligand, suitable for effective cancer therapy. Methods SLNs were synthesized by the high shear, hot homogenization technique. A 2 level 3 factor analysis was used in optimization. Particle size, zeta potential, poly-dispersion index and surface morphology were measured. Drug encapsulation, drug release, release kinetics, nanoparticle stability and chemical structure were determined. LIVE/DEAD® Fluorescence Assay was used to qualify cytotoxicity and Tryphan Blue assay to quantify. Results Cyt-SLNs exhibited a size of 161 ± 2.25nm, a PDI of 0.49 ± 0.15 and zeta potential of -19.8mV. Entrapment fell at 88.87 ± 0.02% and release at 83.5 ± 0.95%. The in vitro release kinetics pointed towards a diffusion based drug release mechanism. SLNs remained stable for 60 days. Cytotoxicity studies revealed that conjugation of the ligand with the RDG peptide resulted in a significant decrease in cell viability in both cell lines. Conclusion Overall, the study suggests that RGD-SLN-cyt can be used for effective cancer therapy.
Read full abstract